|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kennedy AS and Sangro B: Nonsurgical
treatment for localized hepatocellular carcinoma. Curr Oncol Rep.
16:3732014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Blander G and Guarente L: The Sir2 family
of protein deacetylases. Annu Rev Biochem. 73:417–435. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vaquero A, Scher M, Lee D,
Erdjument-Bromage H, Tempst P and Reinberg D: Human SirT1 interacts
with histone H1 and promotes formation of facultative
heterochromatin. Mol Cell. 16:93–105. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huang G, Hao F and Hu X: Downregulation of
microRNA-155 stimulates sevoflurane-mediated cardioprotection
against myocardial ischemia/reperfusion injury by binding to SIRT1
in mice. J Cell Biochem; 2019, View Article : Google Scholar
|
|
7
|
Zhang HX, Li YN, Wang XL, Ye CL, Zhu XY,
Li HP, Yang T and Liu YJ: Probucol ameliorates EMT and lung
fibrosis through restoration of SIRT3 expression. Pulm Pharmacol
Ther. 1018032019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jeong SG and Cho GW: The tubulin
deacetylase sirtuin-2 regulates neuronal differentiation through
the ERK/CREB signaling pathway. Biochem Biophys Res Commun.
482:182–187. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ming M, Han W, Zhao B, Sundaresan NR, Deng
CX, Gupta MP and He YY: SIRT6 promotes COX-2 expression and acts as
an oncogene in skin cancer. Cancer Res. 74:5925–5933. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vitiello M, Zullo A, Servillo L, Mancini
FP, Borriello A, Giovane A, Della Ragione F, D'Onofrio N and
Balestrieri ML: Multiple pathways of SIRT6 at the crossroads in the
control of longevity, cancer, and cardiovascular diseases. Ageing
Res Rev. 35:301–311. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu Y, Xie QR, Wang B, Shao J, Zhang T,
Liu T, Huang G and Xia W: Inhibition of SIRT6 in prostate cancer
reduces cell viability and increases sensitivity to
chemotherapeutics. Protein Cell. 4:702–710. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bai L, Lin G, Sun L, Liu Y, Huang X, Cao
C, Guo Y and Xie C: Upregulation of SIRT6 predicts poor prognosis
and promotes metastasis of non-small cell lung cancer via the
ERK1/2/MMP9 pathway. Oncotarget. 7:40377–40386. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li L, Zhao GD, Shi Z, Qi LL, Zhou LY and
Fu ZX: The Ras/Raf/MEK/ERK signaling pathway and its role in the
occurrence and development of HCC. Oncol Lett. 12:3045–3050. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ni Z, Wang B, Dai X, Ding W, Yang T, Li X,
Lewin S, Xu L, Lian J and He F: HCC cells with high levels of Bcl-2
are resistant to ABT-737 via activation of the ROS-JNK-autophagy
pathway. Free Radic Biol Med. 70:194–203. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ran LK, Chen Y, Zhang ZZ, Tao NN, Ren JH,
Zhou L, Tang H, Chen X, Chen K, Li WY, et al: SIRT6 overexpression
potentiates apoptosis evasion in hepatocellular carcinoma via
BCL2-associated X protein-dependent apoptotic pathway. Clin Cancer
Res. 22:3372–3382. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Feng XX, Luo J, Liu M, Yan W, Zhou ZZ, Xia
YJ, Tu W, Li PY, Feng ZH and Tian DA: Sirtuin 6 promotes
transforming growth factor-β1/H2O2/HOCl-mediated enhancement of
hepatocellular carcinoma cell tumorigenicity by suppressing
cellular senescence. Cancer Sci. 106:559–566. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Song S, Yang Y, Liu M, Liu B, Yang X, Yu
M, Qi H, Ren M, Wang Z, Zou J, et al: MiR-125b attenuates human
hepatocellular carcinoma malignancy through targeting SIRT6. Am J
Cancer Res. 8:993–1007. 2018.PubMed/NCBI
|
|
19
|
Wang Y, Pan T, Wang H, Li L, Li J, Zhang D
and Yang H: Overexpression of SIRT6 attenuates the tumorigenicity
of hepatocellular carcinoma cells. Oncotarget. 8:76223–76230.
2017.PubMed/NCBI
|
|
20
|
Zhang ZG and Qin CY: Sirt6 suppresses
hepatocellular carcinoma cell growth via inhibiting the
extracellular signal-regulated kinase signaling pathway. Mol Med
Rep. 9:882–888. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
López-Terrada D, Cheung SW, Finegold MJ
and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Hum
Pathol. 40:1512–1515. 2009. View Article : Google Scholar
|
|
22
|
Etchegaray JP, Zhong L and Mostoslavsky R:
The histone deacetylase SIRT6: At the crossroads between
epigenetics, metabolism and disease. Curr Top Med Chem.
13:2991–3000. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lerrer B, Gertler AA and Cohen HY: The
complex role of SIRT6 in carcinogenesis. Carcinogenesis.
37:108–118. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kalkavan H and Green DR: MOMP, cell
suicide as a BCL-2 family business. Cell Death Differ. 25:46–55.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Green DR and Llambi F: Cell death
signaling. Cold Spring Harb Perspect Biol. 7:2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Khodapasand E, Jafarzadeh N, Farrokhi F,
Kamalidehghan B and Houshmand M: Is Bax/Bcl-2 ratio considered as a
prognostic marker with age and tumor location in colorectal cancer?
Iran Biomed J. 19:69–75. 2015.PubMed/NCBI
|
|
27
|
Pastor-Idoate S, Rodríguez-Hernández I,
Rojas J, Fernández I, Garcia-Gutierrez MT, Ruiz-Moreno JM,
Rocha-Sousa A, Ramkissoon YD, Harsum S, MacLaren RE, et al: BAX and
BCL-2 polymorphisms, as predictors of proliferative
vitreoretinopathy development in patients suffering retinal
detachment: The Retina 4 project. Acta Ophthalmol. 93:e541–e549.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hassan M, Watari H, AbuAlmaaty A, Ohba Y
and Sakuragi N: Apoptosis and molecular targeting therapy in
cancer. Biomed Res Int. 2014:1508452014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Goldar S, Khaniani MS, Derakhshan SM and
Baradaran B: Molecular mechanisms of apoptosis and roles in cancer
development and treatment. Asian Pac J Cancer Prev. 16:2129–2144.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sui Y, Zheng X and Zhao D: Rab31 promoted
hepatocellular carcinoma (HCC) progression via inhibition of cell
apoptosis induced by PI3K/AKT/Bcl-2/BAX pathway. Tumour Biol.
36:8661–8670. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Morigi M, Perico L and Benigni A: Sirtuins
in renal health and disease. J Am Soc Nephrol. 29:1799–1809. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xing X, Gu X, Ma T and Ye H: Biglycan
up-regulated vascular endothelial growth factor (VEGF) expression
and promoted angiogenesis in colon cancer. Tumour Biol.
36:1773–1780. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Miyake M, Goodison S, Lawton A,
Gomes-Giacoia E and Rosser CJ: Angiogenin promotes tumoral growth
and angiogenesis by regulating matrix metallopeptidase-2 expression
via the ERK1/2 pathway. Oncogene. 34:890–901. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sun Y, Liu WZ, Liu T, Feng X, Yang N and
Zhou HF: Signaling pathway of MAPK/ERK in cell proliferation,
differentiation, migration, senescence and apoptosis. J Recept
Signal Transduct Res. 35:600–604. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang CC, Wu DW, Lin PL and Lee H:
Paxillin promotes colorectal tumor invasion and poor patient
outcomes via ERK-mediated stabilization of Bcl-2 protein by
phosphorylation at Serine 87. Oncotarget. 6:8698–8708.
2015.PubMed/NCBI
|
|
36
|
Kim JH, Lee JM, Kim JH and Kim KR:
Fluvastatin activates sirtuin 6 to regulate sterol regulatory
element-binding proteins and AMP-activated protein kinase in HepG2
cells. Biochem Biophys Res Commun. 503:1415–1421. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Parenti MD, Grozio A, Bauer I, Galeno L,
Damonte P, Millo E, Sociali G, Franceschi C, Ballestrero A,
Bruzzone S, et al: Discovery of novel and selective SIRT6
inhibitors. J Med Chem. 57:4796–4804. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sociali G, Galeno L, Parenti MD, Grozio A,
Bauer I, Passalacqua M, Boero S, Donadini A, Millo E, Bellotti M,
et al: Quinazolinedione SIRT6 inhibitors sensitize cancer cells to
chemotherapeutics. Eur J Med Chem. 102:530–539. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Damonte P, Sociali G, Parenti MD, Soncini
D, Bauer I, Boero S, Grozio A, Holtey MV, Piacente F, Becherini P,
et al: SIRT6 inhibitors with salicylate-like structure show
immunosuppressive and chemosensitizing effects. Bioorg Med Chem.
25:5849–5858. 2017. View Article : Google Scholar : PubMed/NCBI
|
